Eduardo Cronemberger
18 Papers
13 Citations
Eduardo Cronemberger is an academic researcher. The author has contributed to research in topics: Cancer & Breast cancer. The author has an hindex of 3, co-authored 10 publications.
Chat about Author
Papers
Biomarker Analysis of the Phase III NALA Study of Neratinib + Capecitabine versus Lapatinib + Capecitabine in Patients with Previously Treated Metastatic Breast Cancer.
Cristina Saura,Cristina Saura,Judit Matito,Mafalda Oliveira,Hans Wildiers,Adam M. Brufksy,S Waters,Sara A. Hurvitz,Beverly Moy,Sung-Bae Kim,William J. Gradishar,Geraldo Silva Queiroz,Eduardo Cronemberger,Gerald J. Wallweber,Judith Bebchuk,Kiana Keyvanjah,Alshad S. Lalani,Richard A. Bryce,Ana Vivancos,Lisa D. Eli,Suzette Delaloge +20 more
TL;DR: In this article, the authors evaluated correlations between exploratory biomarkers and progression-free survival (PFS) in NALA (NCT01808573), a randomized phase III trial comparing N+C with lapatinib + capecitabine (L+C) in 621 patients with HER2-positive (HER2+) metastatic breast cancer (MBC).
A phase 2 randomized clinical trial of abiraterone plus ADT, apalutamide, or abiraterone and apalutamide in patients with advanced prostate cancer with non-castrate testosterone levels (LACOG 0415).
Fernando C. Maluf,Fabio A.B. Schutz,Eduardo Cronemberger,Murilo Luz,Suelen Patrícia dos Santos Martins,David Queiroz Borges Muniz,Diogo Assed Bastos,Flavio Mavignier Carcano,Oren Smaletz,Andrey Soares,Fabio A. Peixoto,Andrea J. Pereira de Santana Gomes,Felipe Melo Cruz,Fabio Franke,Daniel Herchenhorn,Telma Santos,Vanessa Carvalho Fabricio,Rosemarie Gidekel,Gustavo Werutsky,Rafaela Gomes de Jesus,Vinicius Carrera Souza,Andre P. Fay +21 more
TL;DR: The LACOG 0415 trial as mentioned in this paper showed that ADT-free alternatives provide a high PSA response in advanced CSPC, although the APA arm did not reach the expected rate of PSA of ≤ 0.2 ng/mL at week 25.
15
Real-World Molecular Testing and Treatment Patterns in Brazilian Patients with Newly Diagnosed Locally Advanced or Metastatic NSCLC.
Eduardo Cronemberger,Clarissa Baldotto,Felipe Costa de Andrade Marinho,Pedro De Marchi,Luiz H. Araujo,Fabio Franke,Paulo Salles,Aknar Calabrich,Thaís Almeida,M. Custodio,Andre Santa Maria,Marcelo Horacio Pereira,Gilberto de Castro +12 more
TL;DR: The findings provide relevant information for prescribers and policy decision-makers by highlighting the unmet needs of patients and the importance of molecular testing in newly diagnosed locally advanced or metastatic lung adenocarcinoma.
6
Phase II randomized study of abiraterone acetate plus prednisone (AAP) added to ADT versus apalutamide alone (APA) versus AAP+APA in patients with advanced prostate cancer with noncastrate testosterone levels: (LACOG 0415).
Fernando C. Maluf,Andre P. Fay,Vinicius Carrera Souza,Fabio A.B. Schutz,Oren Smaletz,Daniel Herchenhorn,Vanessa Carvalho Fabricio,Rosemarie Gidekel,Eduardo Cronemberger,Murilo Luz,Suelen Patrícia dos Santos Martins,David Queiroz Borges Muniz,Fabio Franke,Fabio A. Peixoto,Flavio Mavignier Carcano,Andrea J. Pereira de Santana Gomes,Felipe Melo Cruz,Rafaela Gomes,Paulo Ricardo Santos Nunes Filho,Gustavo Werutsky +19 more
TL;DR: ADT combined with AAP, APA, enzalutamide or docetaxel are among the standard treatment options to patients with hormone sensitive advanced/metastatic prostate cancer (PC).
4
Abstract P1-08-29: Current status of clinical and pathological characteristics of breast cancer patients in Brazil: Results of the AMAZONA III study (GBECAM 0115)
Daniela Dornelles Rosa,Carlos Barrios,José Bines,G Werustky,Eduardo Cronemberger,Geraldo Silva Queiroz,Vladmir Cláudio Cordeiro de Lima,Ruffo Freitas-Junior,J Couto,K Emerenciano,H Resende,Susanne Crocamo,Tomás Reinert,B Van Eyil,Y. Neron,V Dybal,Nicolas Lazaretti,Rita de Cassia Costamilan,Diocésio Alves Pinto de Andrade,C. Mathias,Giovana Zerwes Vacaro,G. Borges,Kátia Luz Torres,Alessandra Morelle,CA Sampaio Filho,Max S. Mano,Facundo Zaffaroni,Sergio Daniel Simon +27 more
TL;DR: The majority of patients were detected through symptomatic BC and therefore a significant proportion is still diagnosed in stages III and IV and among other factors, these findings could have a significant impact in treatment outcomes.
4